Skip to content
Open access

Tuberculosis Incidence and Predictors Among People Living With HIV After Isoniazid–Rifapentine (3HP) Preventive Therapy in Ethiopia: A Retrospective Cohort Study

Jan 2026 · Journal of Tropical Medicine · Vol 2026 · 0 citations · 31 references
Medicine

TL;DR

Significant risk factors for TB incidence among HIV‐positive individuals were identified, highlighting the need for targeted preventive strategies to address these risks, particularly in high‐risk populations.

Abstract

Background Global reports of tuberculosis (TB) in 2024 estimated 10.7 million cases, of which 5.8% were HIV‐positive individuals. Despite the implementation of TB preventive therapy, TB incidence rates remain high, especially among HIV‐infected patients. Methods A retrospective cohort study was conducted from 1 October 2020 to 31 October 2025. A two‐stage sampling procedure was used to select both health facilities and study participants. First, seven public health facilities in the West Arsi zone were selected using simple random sampling. Second, 426 people living with HIV were randomly selected from ART registers of the selected health facilities. The data were collected via the Kobo Toolbox and analysed via SPSS Version 26. Kaplan‒Meier estimates were used for time‒event distribution; for survival, curves were compared via log‐rank tests. Risk factors for active TB were identified through Cox proportional hazards regression, with significance at p < 0.05. Results A total of 426 HIV‐positive patients were followed for 1867 person‐years, during which 71 individuals (16.7% of participants) developed TB, resulting in a TB incidence density rate of 3.78 per 100 person‐years. The identified risk factors for developing active TB were WHO Clinical Stages II to IV (adjusted hazard ratios [AHR] = 3.44 [95% CI: 1.50–7.85], 5.41 [95% CI: 2.47–11.84] and 7.52 [95% CI: 3.09–18.32], respectively). Participants who received daily isoniazid for 6 months (INH/6H) and those who did not receive any TPT regimen had significantly greater hazard of developing TB compared to those receiving 3HP (AHR = 5.01, 95% CI: 2.35–10.65 and AHR = 12.53, 95% CI: 5.65–27.79, respectively). Similarly, individuals with haemoglobin (HBg) levels < 11 g/dL had a markedly increased risk of TB (AHR = 2.46, 95% CI: 1.31, 4.60), as did those with a body mass index < 18.5 kg/m2 (AHR = 4.37, 95% CI: 2.14, 8.95). Conclusion This study revealed that 16.7% of participants developed active TB. Significant risk factors for TB incidence among HIV‐positive individuals were identified, highlighting the need for targeted preventive strategies to address these risks, particularly in high‐risk populations.

Read PDF

Similar papers

Open access Sep 2026

Independent Predictors of Tuberculosis Coinfection among People Living with HIV in Medan, Indonesia: A Case-Control Study

Tuberculosis (TB) remains a major cause of morbidity among people living with HIV (PLHIV), particularly in high-burden countries such as Indonesia. This study aimed to identify factors independently associated with TB-HIV coinfection among PLHIV in Medan, Indonesia. An unmatched case-control study with a 1:3 case-to-co...

Silvi Anggraeni M, Rahayu Lubis, Sri Novita Lubis · 0 citations
Open access 2026

Factors Associated With Tuberculosis Preventive Therapy Uptake among Eligible Children under Fifteen Years at Kakamega County Referral Hospital, Kenya

Background: Tuberculosis (TB) remains a significant global health concern, with efforts aimed at ending the epidemic by 2035. Tuberculosis Preventive Therapy (TPT) is a key intervention to prevent progression from latent TB infection to active disease, especially in children under fifteen, who were at higher risk parti...

Jackson K. Limo, David Masinde, S. Korir · 0 citations
Review Open access Jan 2026

Tuberculosis Treatment Uptake and Outcomes Among HIV-Positive Patients on Antiretroviral Therapy at a Tertiary Health Facility in South-South, Nigeria

Background There is a significant intersection between Tuberculosis (TB) and HIV, which has contributed greatly to the disease burden, especially in Nigeria. Among approximately 1.9 million people living with HIV (PLHIV), an estimated 46,000 also had TB in 2019 alone. HIV-associated TB incidence has continuously increa...

A. Aigbokhaode, A. Jegede, N. Orhue et al. · 0 citations
Review Open access Sep 2026

Four-year mortality and ART outcomes among adults with HIV and microbiologically confirmed tuberculosis during early ULAM rollout at a Cape Town district hospital

Background. Tuberculosis (TB) is the leading cause of mortality in people living with HIV (PLWH). In 2015, the World Health Organization advocated use of the urine lipoarabinomannan (ULAM) assay to accelerate the diagnosis of TB, and thus its treatment, in selected patients with HIV. Objectives. To describe the demogra...

A. Howard, L. Mapahla, D. Maughan · 0 citations
Open access Sep 2026

Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Selected Facilities of O.R. Tambo District Municipality, Eastern Cape, South Africa: A Retrospective Cohort Study

Background: Tuberculosis (TB) remains a major global health concern, particularly in low- and middle-income countries, due to its high prevalence, mortality, and economic impact. The emergence of drug-resistant tuberculosis (DR-TB) has intensified this burden, posing significant challenges to disease control and manage...

Yanga Somjobo, L. Faye, M. C. Hosu · 0 citations
Open access Sep 2026

All-cause mortality and associated factors among adults living with HIV receiving antiretroviral therapy in the Sughd region of Tajikistan: a retrospective cohort study, 2013–2022

Despite expanded access to antiretroviral therapy (ART), HIV-related mortality remains a concern in resource-limited settings. We assessed all-cause mortality and the factors associated with death among adults receiving ART in the Sughd region of Tajikistan. We conducted a retrospective cohort study of adu...

E. Qurbonov, R. Horth, A. Mirzoev et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.